Compass pathways stock forecast.

See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... CMPS : Long term COMPASS Pathways plc stock forecast for 2022, 2023 (1 year) - 2025 - 2027 (5 year) - 2030, and 2032 (10 year). Forecast for 2024 Jan. is $6.19 ...It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.

See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Web

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...

Psychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...CMPS: Get the latest COMPASS Pathways stock price and detailed information including CMPS news, historical charts and realtime prices. Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Ce...On average, Wall Street analysts predict. that Compass Pathways's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction forecasts a potential upside of 857.36% from the current CMPS share price of $5.98.COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.

The COMPASS Pathways plc stock forecast for tomorrow is $ 5.02, which would represent a -4.68% loss compared to the current price. In the next week, the price of CMPS is expected to decrease by -2.62% and hit $ 5.13. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting.

In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...

Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore. On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.You can buy or sell CMPS and other ETFs, options, and stocks. Sign up. About CMPS. Compass Pathways Plc is an investment holding company. It operates through ...A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...

06:48 PM ET 11/23/2020. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the ...COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.COMPASS Pathways Plc American Depository Shares (CMPS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Web

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...Web

69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.Hedge funds don't have many shares in COMPASS Pathways. Our data shows that Atai Life Sciences N.V. is the largest shareholder with 23% of shares outstanding.COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.WebLearn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...Web

The average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ATAI) forecast ROE …

At close: 04:00PM EST. 6.06 0.00 (0.00%) After hours: 07:09PM EST. Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from ...

Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...WebSee the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest Alpha Lithium Corporation (APHLF) stock quote, history, news and other vital information to help you with your stock trading and investing.Jul 6, 2023 · The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC. See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.WebThese psychedelic stocks are speculative but could potentially offer massive upside. MindMed ( MNMD ): Positioned to rapidly expand its GAD therapy this year. COMPASS Pathways ( CMPS ): COMP360 ...16 de ago. de 2023 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...NasdaqGS:CMPS Earnings and Revenue Growth April 12th 2021. COMPASS Pathways is not owned by hedge funds. Our data shows that ATAI Life Sciences AG is the largest shareholder with 22% of shares ...

Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ. A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Instagram:https://instagram. how much are us half dollars wortharp stockrobinhood vs acorns vs webullnasdaq adbe financials The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...Of course COMPASS Pathways may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying . startups to investjets price COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. ijh ticker 69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...WebWe note that hedge funds don't have a meaningful investment in COMPASS Pathways. Atai Life Sciences N.V. is currently the company's largest shareholder with 19% of shares outstanding. The second ...